Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Correction of Severe Deviated Nose by Intermediate Short Osteotomy.

Abbasi R, Dowlati A, Seif Rabiei MA, Hashemian F.

World J Plast Surg. 2019 May;8(2):208-212. doi: 10.29252/wjps.8.2.208.

2.

A Phase I Pharmacokinetic Study of Belinostat in Patients with Advanced Cancers and Varying Degrees of Liver Dysfunction.

Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP.

Br J Clin Pharmacol. 2019 Jul 4. doi: 10.1111/bcp.14054. [Epub ahead of print]

PMID:
31271459
3.

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.

Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, Le MH, Coussens LM, Rugo HS.

Ther Adv Med Oncol. 2019 Jun 21;11:1758835919854238. doi: 10.1177/1758835919854238. eCollection 2019.

4.

Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF.

Nat Rev Cancer. 2019 Jul;19(7):415. doi: 10.1038/s41568-019-0164-2.

PMID:
31175338
5.

A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.

Sharman JP, Wheler JJ, Einhorn L, Dowlati A, Shapiro GI, Hilton J, Burke JM, Siddiqi T, Whiting N, Jalal SI.

Invest New Drugs. 2019 Aug;37(4):738-747. doi: 10.1007/s10637-019-00768-6. Epub 2019 Apr 16.

6.

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF.

Nat Rev Cancer. 2019 May;19(5):289-297. doi: 10.1038/s41568-019-0133-9. Review. Erratum in: Nat Rev Cancer. 2019 Jun 7;:.

PMID:
30926931
7.

Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer.

Bhateja P, Chiu M, Wildey G, Lipka MB, Fu P, Yang MCL, Ardeshir-Larijani F, Sharma N, Dowlati A.

Cancer Med. 2019 Apr;8(4):1459-1466. doi: 10.1002/cam4.2023. Epub 2019 Feb 17.

8.

Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.

Hsu WH, Zhao X, Zhu J, Kim IK, Rao G, McCutcheon J, Hsu ST, Teicher B, Kallakury B, Dowlati A, Zhang YW, Giaccone G.

J Thorac Oncol. 2019 Jun;14(6):1032-1045. doi: 10.1016/j.jtho.2019.01.028. Epub 2019 Feb 14. Erratum in: J Thorac Oncol. 2019 Aug;14(8):1484.

PMID:
30771522
9.

Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy.

Grubb WR, Machtay M, Dowlati A, Biswas T.

Pract Radiat Oncol. 2019 Mar;9(2):e129-e133. doi: 10.1016/j.prro.2018.11.002. Epub 2019 Jan 18. No abstract available.

PMID:
30665865
10.

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.

Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S, Meric-Bernstam F, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC.

Ann Oncol. 2019 Feb 1;30(2):325-331. doi: 10.1093/annonc/mdy539.

11.

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, Powderly JD, Vaishampayan UN, Verschraegen C, Grote HJ, von Heydebreck A, Chin K, Gulley JL.

JAMA Oncol. 2019 Mar 1;5(3):351-357. doi: 10.1001/jamaoncol.2018.5428.

12.

High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.

Hashemi Sadraei N, Feng Y, Du L, Fu P, Haque S, Dowlati A, Gollamudi J, Pennell NA, Mekhail T, Avril S, Farver C, Gerson SL, Sharma N.

Lung Cancer. 2018 Dec;126:48-54. doi: 10.1016/j.lungcan.2018.08.011. Epub 2018 Aug 13.

PMID:
30527192
13.

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.

Goldberg ME, Montesion M, Young L, Suh J, Greenbowe J, Kennedy M, Giaccone G, Akerley WL, Dowlati A, Creelan BC, Hicks JK, Hesketh PJ, Kelly KL, Riess JW, Miller VA, Stephens PJ, Frampton GM, Ali S, Gregg JP, Albacker LA.

PLoS One. 2018 Nov 27;13(11):e0208097. doi: 10.1371/journal.pone.0208097. eCollection 2018.

14.

Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.

Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P.

Clin Cancer Res. 2019 Jan 1;25(1):210-221. doi: 10.1158/1078-0432.CCR-18-1278. Epub 2018 Oct 16.

15.

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.

Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Santana-Davila R, Williams CC, Hoffmann KG, Hughes M.

J Natl Compr Canc Netw. 2018 Oct;16(10):1171-1182. doi: 10.6004/jnccn.2018.0079.

PMID:
30323087
16.

Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma.

He T, McColl K, Sakre N, Chen Y, Wildey G, Dowlati A.

Mol Oncol. 2018 Dec;12(12):2124-2135. doi: 10.1002/1878-0261.12386. Epub 2018 Oct 23.

17.

Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma.

Miller TE, Yang M, Bajor D, Friedman JD, Chang RYC, Dowlati A, Willis JE, Sadri N.

J Clin Pathol. 2018 Dec;71(12):1108-1115. doi: 10.1136/jclinpath-2018-205396. Epub 2018 Sep 18.

PMID:
30228211
18.

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.

Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA.

J Clin Oncol. 2018 Aug 10;36(23):2386-2394. doi: 10.1200/JCO.2018.77.7672. Epub 2018 Jun 15.

19.

A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer.

Guo NL, Dowlati A, Raese RA, Dong C, Chen G, Beer DG, Shaffer J, Singh S, Bokhary U, Liu L, Howington J, Hensing T, Qian Y.

EBioMedicine. 2018 Jun;32:102-110. doi: 10.1016/j.ebiom.2018.05.025. Epub 2018 Jun 1.

20.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.

Invest New Drugs. 2019 Feb;37(1):87-97. doi: 10.1007/s10637-018-0610-0. Epub 2018 May 21.

21.

KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.

Ardeshir-Larijani F, Bhateja P, Lipka MB, Sharma N, Fu P, Dowlati A.

Clin Lung Cancer. 2018 Jul;19(4):e489-e501. doi: 10.1016/j.cllc.2018.03.005. Epub 2018 Mar 16.

PMID:
29627316
22.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

23.

The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells.

De S, Lindner DJ, Coleman CJ, Wildey G, Dowlati A, Stark GR.

Cancer Res. 2018 May 1;78(9):2396-2406. doi: 10.1158/0008-5472.CAN-17-1920. Epub 2018 Feb 13.

24.

Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies.

Caimi PF, Cooper BW, William BM, Dowlati A, Barr PM, Fu P, Pink J, Xu Y, Lazarus HM, de Lima M, Gerson SL.

Oncotarget. 2017 Aug 9;8(45):79864-79875. doi: 10.18632/oncotarget.20094. eCollection 2017 Oct 3.

25.

Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer.

McColl K, Wildey G, Sakre N, Lipka MB, Behtaj M, Kresak A, Chen Y, Yang M, Velcheti V, Fu P, Dowlati A.

Oncotarget. 2017 Aug 28;8(43):73745-73756. doi: 10.18632/oncotarget.20572. eCollection 2017 Sep 26.

26.

Relationship between phase I study duration and symptom burden.

Treasure M, Daly B, Fu P, Kerpedjieva S, Dowlati A, Meropol NJ.

Support Care Cancer. 2018 Mar;26(3):731-737. doi: 10.1007/s00520-017-3879-1. Epub 2017 Oct 5.

PMID:
28980072
27.

Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.

Bhateja P, Dowlati A, Sharma N.

Invest New Drugs. 2018 Jun;36(3):435-441. doi: 10.1007/s10637-017-0515-3. Epub 2017 Oct 2.

PMID:
28971268
28.

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.

Gerber DE, Swanson P, Lopez-Chavez A, Wong L, Dowlati A, Pennell NA, Cronier DM, Qin A, Ilaria R Jr, Cosaert J, Shahir A, Baggstrom MQ.

Lung Cancer. 2017 Sep;111:108-115. doi: 10.1016/j.lungcan.2017.07.009. Epub 2017 Jul 18.

29.

Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer.

Kang KH, Efird JT, Sharma N, Yang M, Dowlati A, Linden P, Machtay M, Biswas T.

Future Oncol. 2017 Jul;13(16):1405-1414. doi: 10.2217/fon-2017-0045. Epub 2017 Jul 7.

PMID:
28685599
30.

[How I explore…. HLA class II by ultrastructure in toxic epidermal necrolysis].

Piérard GE, Dowlati A, Piérard-Franchimont C, Paquet P, Delvenne P.

Rev Med Liege. 2016 Jun;71(6):298-301. Review. French.

31.

Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.

Tacastacas JD, Chan DV, Carlson S, Gerson SL, Dowlati A, Fu P, Lu K, Groft S, Rosenjack J, Honda K, McCormick TS, Cooper KD.

JAMA Dermatol. 2017 May 1;153(5):413-420. doi: 10.1001/jamadermatol.2016.5793. Erratum in: JAMA Dermatol. 2017 May 1;153(5):479.

32.

Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.

Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, Massion PP, Rudin CM, Poirier JT.

Cancer Cell. 2017 Feb 13;31(2):286-299. doi: 10.1016/j.ccell.2017.01.006.

33.

A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.

Wu B, Lewis LD, Harvey RD, Rasmussen E, Gamelin E, Sun YN, Friberg G, Koyner JL, Dowlati A, Maitland ML.

Clin Pharmacol Ther. 2017 Aug;102(2):313-320. doi: 10.1002/cpt.617. Epub 2017 Jun 9.

PMID:
28074547
34.

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).

Augert A, Zhang Q, Bates B, Cui M, Wang X, Wildey G, Dowlati A, MacPherson D.

J Thorac Oncol. 2017 Apr;12(4):704-713. doi: 10.1016/j.jtho.2016.12.011. Epub 2016 Dec 19.

35.

RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.

Sakre N, Wildey G, Behtaj M, Kresak A, Yang M, Fu P, Dowlati A.

Oncotarget. 2017 Jan 24;8(4):5992-6002. doi: 10.18632/oncotarget.13362.

36.

Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine.

Oleinick NL, Biswas T, Patel R, Tao M, Patel R, Weeks L, Sharma N, Dowlati A, Gerson SL, Fu P, Zhang J, Machtay M.

Radiother Oncol. 2016 Nov;121(2):335-341. doi: 10.1016/j.radonc.2016.10.007. Epub 2016 Nov 9.

PMID:
27838149
37.

Evaluating the role of phase I expansion cohorts in oncologic drug development.

Norris RE, Behtaj M, Fu P, Dowlati A.

Invest New Drugs. 2017 Feb;35(1):108-114. doi: 10.1007/s10637-016-0394-z. Epub 2016 Oct 7. Review.

PMID:
27718038
38.

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.

Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM.

Oncologist. 2016 Oct;21(10):1163-1164. Epub 2016 Sep 30.

39.

Genomic alterations in small cell lung cancer and their clinical relevance.

Wildey G, Dowlati A.

Transl Lung Cancer Res. 2016 Aug;5(4):450-1. doi: 10.21037/tlcr.2016.07.05. No abstract available.

40.

Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.

Fu P, Pennell NA, Sharma N, Yi Q, Dowlati A.

Rev Recent Clin Trials. 2017;12(1):51-58. doi: 10.2174/1574887111666160916130423.

PMID:
27633965
41.

Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data.

Kim E, Biswas T, Bakaki P, Dowlati A, Sharma N, Machtay M.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):e163-e169. doi: 10.1016/j.prro.2016.01.011. Epub 2016 Jan 28.

PMID:
27142494
42.

A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.

Dowlati A, Vlahovic G, Natale RB, Rasmussen E, Singh I, Hwang YC, Rossi J, Bass MB, Friberg G, Pickett CA.

Clin Cancer Res. 2016 Sep 15;22(18):4574-84. doi: 10.1158/1078-0432.CCR-15-2145. Epub 2016 Apr 13.

43.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.

44.

Clinical correlation of extensive-stage small-cell lung cancer genomics.

Dowlati A, Lipka MB, McColl K, Dabir S, Behtaj M, Kresak A, Miron A, Yang M, Sharma N, Fu P, Wildey G.

Ann Oncol. 2016 Apr;27(4):642-7. doi: 10.1093/annonc/mdw005. Epub 2016 Jan 22.

45.

Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.

Greenberg EF, McColl KS, Zhong F, Wildey G, Dowlati A, Distelhorst CW.

Cell Death Dis. 2015 Dec 31;6:e2034. doi: 10.1038/cddis.2015.355.

46.

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ.

Sci Transl Med. 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459.

47.

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.

Halmos B, Pennell NA, Fu P, Saad S, Gadgeel S, Otterson GA, Mekhail T, Snell M, Kuebler JP, Sharma N, Dowlati A.

Oncologist. 2015 Nov;20(11):1298-303. doi: 10.1634/theoncologist.2015-0136. Epub 2015 Aug 25.

48.

Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies.

Gerber DE, Paik PK, Dowlati A.

Am Soc Clin Oncol Educ Book. 2015:147-62. doi: 10.14694/EdBook_AM.2015.35.147. Review.

49.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS.

Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.

50.

CD30 is a potential therapeutic target in malignant mesothelioma.

Dabir S, Kresak A, Yang M, Fu P, Wildey G, Dowlati A.

Mol Cancer Ther. 2015 Mar;14(3):740-6. doi: 10.1158/1535-7163.MCT-14-0972. Epub 2015 Jan 14.

Supplemental Content

Loading ...
Support Center